Cardiovascular

FDA approves Ferriprox for thalassemia patients with iron overload from blood transfusions

The U.S. Food and Drug Administration has Ferriprox (deferiprone) for the treatment of iron overload caused by blood transfusions in patients with thalassemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares